| Hydralazine, antinuclear antibodies, and the lupus syndrome. | |
| | |
MedLine Citation:
|
PMID: 6802356 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The incidence of patients with positive antinuclear antibody test results rose during three years of treatment with hydralazine. At the end of that period over half of the patients (both rapid and slow acetylators) had titres exceeding 1/20, but the rate of rise was faster in the slow acetylators than in the rapid. There was a significant relation between the cumulative dose of hydralazine and the proportion of patients found to have antinuclear factors. Fewer black patients had positive test results than white. Patients whose antinuclear antibody test results changed fron negative to positive during the study showed this change five to 26 months after beginning treatment. Some patients showed a substantial fall in antinuclear antibody titre even though hydralazine was continued. From these findings patients in whom test results for antinuclear antibody became positive during treatment with hydralazine need not have the drug stopped unless they have clinical features of the lupus syndrome. |
| | |
Authors:
|
R Mansilla-Tinoco; S J Harland; P J Ryan; R M Bernstein; C T Dollery; G R Hughes; C J Bulpitt; A Morgan; J M Jones |
Related Documents
:
|
2108246 - Clinical value of an integrated elisa system for the detection of 6 autoantibodies (ssd... 3839896 - The design and use of a charting system for automatic record keeping during extracorpor... 17534796 - Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hem... 8478856 - Treatment of systemic lupus erythematosus by prolonged administration of high dose intr... 23279026 - Acetaminophen administration in a patient with gilbert's syndrome. 22795716 - Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patien... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: British medical journal (Clinical research ed.) Volume: 284 ISSN: 0267-0623 ISO Abbreviation: Br Med J (Clin Res Ed) Publication Date: 1982 Mar |
Date Detail:
|
Created Date: 1982-06-21 Completed Date: 1982-06-21 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 8302911 Medline TA: Br Med J (Clin Res Ed) Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 936-9 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetylation Antibodies, Antinuclear / immunology* Dose-Response Relationship, Drug Female Humans Hydralazine / administration & dosage, adverse effects* Hypertension / drug therapy Lupus Erythematosus, Systemic / chemically induced*, immunology Male Phenotype Syndrome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Antinuclear; 86-54-4/Hydralazine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neonatal screening for sickle haemoglobinopathies in Birmingham.
Next Document: Missed injuries of the spinal cord.